Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Key Highlights
- ➤1L ORR reached 75% and 2L ORR reached 67% with petosemtamab combinations
- ➤Left-sided 1L tumors achieved an 81% objective response rate
- ➤Disease control rates reached 95% in 1L and 93% in 2L patients
- ➤Global Phase 3 LiGeR-CRC trials continue actively enrolling metastatic colorectal cancer patients
- ➤Treatment discontinuations from petosemtamab-related adverse events were 5% with FOLFOX and 3% with FOLFIRI
Expert Statements
Ruth Vera, Medical Oncology Department, Hospital Universitario de Navarra, and study investigator
“Despite advances in the treatment of metastatic colorectal cancer, outcomes remain poor for many patients once disease has spread, including those with RAS/BRAF wild-type disease who may face limited options after standard chemotherapy and targeted therapy”
Ruth Vera, Medical Oncology Department, Hospital Universitario de Navarra, and study investigator
“The encouraging response rates observed in both the first- and second-line settings, along with the maturation of the dataset over time, suggest that treatment with petosemtamab plus chemotherapy may offer a potential new approach for these patients.”
Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab
“These updated Phase 2 results presented at ESMO continue to build on the encouraging clinical efficacy of petosemtamab”
Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab
“The confirmation of previously unconfirmed responses with longer follow-up further reinforces the durability of responses observed across treatment lines and strengthens our confidence in petosemtamab.”
Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab
“The data provide a compelling rationale for our ongoing global Phase 3 trials, where we aim to establish the potential benefit for patients in 1L and 2L settings.”
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
* Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC)
Get started
Create a free account to read the full story.